Polycythemia vera epidemiology and demographics: Difference between revisions
Shyam Patel (talk | contribs) (→Age) |
Shyam Patel (talk | contribs) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{MJK}} {{shyam}} | {{CMG}}{{AE}}{{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
The incidence of polycythemia vera is approximately 0.7 to 2.6 per 100,000 individuals in the US.<ref name="seercancergov">National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/</ref> | The incidence of polycythemia vera is approximately 0.7 to 2.6 per 100,000 individuals in the US.<ref name="seercancergov">National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/</ref> The prevalence of polycythemia vera is 48 to 57 cases per 100,000 individuals in the United States. Males are more commonly affected than females. The life expectancy is variable but is typically more than 10 years for patients who have uncomplicated polycythemia vera and is significantly shorter in the case of post-PV myelofibrosis or post-PV acute myeloid leukemia. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
| Line 14: | Line 15: | ||
===Age=== | ===Age=== | ||
The median age of polycythemia vera is 61 years.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368 }} </ref><ref name="pmid25353086">{{cite journal| author=Verstovsek S, Komrokji RS| title=Novel and emerging therapies for the treatment of polycythemia vera. | journal=Expert Rev Hematol | year= 2015 | volume= 8 | issue= 1 | pages= 101-13 | pmid=25353086 | doi=10.1586/17474086.2015.972359 | pmc=4934659 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25353086 }} </ref> Polycythemia vera occurs in all age groups (including children). The incidence increases with age. Polycythemia vera commonly affects people older than 60.<ref name="seercancergov">National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/</ref><ref>{{cite journal | author = Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M | title = Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. | journal = Haematologica | volume = 88 | issue = 1 | pages = 13-8 | year = 2003 | id = PMID 12551821}}</ref><ref name="pvsg">Berlin, NI. (1975). "Diagnosis and classification of polycythemias". ''Semin Hematol'' '''12''': 339.</ref> Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368 }} </ref> | The median age of polycythemia vera is 61 years.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368 }} </ref><ref name="pmid25353086">{{cite journal| author=Verstovsek S, Komrokji RS| title=Novel and emerging therapies for the treatment of polycythemia vera. | journal=Expert Rev Hematol | year= 2015 | volume= 8 | issue= 1 | pages= 101-13 | pmid=25353086 | doi=10.1586/17474086.2015.972359 | pmc=4934659 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25353086 }} </ref> Polycythemia vera occurs in all age groups (including children). The incidence increases with age. Polycythemia vera commonly affects people older than 60 since mutations are more likely to develop with aging.<ref name="seercancergov">National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/</ref><ref>{{cite journal | author = Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M | title = Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. | journal = Haematologica | volume = 88 | issue = 1 | pages = 13-8 | year = 2003 | id = PMID 12551821}}</ref><ref name="pvsg">Berlin, NI. (1975). "Diagnosis and classification of polycythemias". ''Semin Hematol'' '''12''': 339.</ref> Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.<ref name="pmid26324368">{{cite journal| author=Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al.| title=Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. | journal=J Clin Oncol | year= 2015 | volume= 33 | issue= 33 | pages= 3953-60 | pmid=26324368 | doi=10.1200/JCO.2015.61.6474 | pmc=4979103 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26324368 }} </ref> | ||
===Gender=== | ===Gender=== | ||
| Line 20: | Line 21: | ||
===Life expectancy=== | ===Life expectancy=== | ||
The life expectancy after diagnosis is 13.5 years.<ref name="pmid25353086">{{cite journal| author=Verstovsek S, Komrokji RS| title=Novel and emerging therapies for the treatment of polycythemia vera. | journal=Expert Rev Hematol | year= 2015 | volume= 8 | issue= 1 | pages= 101-13 | pmid=25353086 | doi=10.1586/17474086.2015.972359 | pmc=4934659 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25353086 }} </ref> | The life expectancy after diagnosis is 13.5 years.<ref name="pmid25353086">{{cite journal| author=Verstovsek S, Komrokji RS| title=Novel and emerging therapies for the treatment of polycythemia vera. | journal=Expert Rev Hematol | year= 2015 | volume= 8 | issue= 1 | pages= 101-13 | pmid=25353086 | doi=10.1586/17474086.2015.972359 | pmc=4934659 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25353086 }} </ref> For patients who develop post-PV myelofibrosis or post-PV acute myeloid leukemia, the life expectancy is significantly shorter. Please see ''Natural History, Complications, and Prognosis'' section. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 01:06, 19 February 2018
|
Polycythemia vera Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia vera epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polycythemia vera epidemiology and demographics |
|
Risk calculators and risk factors for Polycythemia vera epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
The incidence of polycythemia vera is approximately 0.7 to 2.6 per 100,000 individuals in the US.[1] The prevalence of polycythemia vera is 48 to 57 cases per 100,000 individuals in the United States. Males are more commonly affected than females. The life expectancy is variable but is typically more than 10 years for patients who have uncomplicated polycythemia vera and is significantly shorter in the case of post-PV myelofibrosis or post-PV acute myeloid leukemia.
Epidemiology and Demographics
Incidence
The incidence of polycythemia vera is approximately 0.7 to 2.6 per 100,000 individuals in the US.[1]
Prevalence
The prevalence of polycythemia vera is 48 to 57 cases per 100,000 individuals in the United States. This represents the age-adjusted prevalence as of 2010. The prevalence of polycythemia vera is 5 to 30 cases per 100,000 individuals in Europe.[2] Approximately 148,000 persons are living with polycythemia vera currently.[3] It is likely that this is an underestimate of the true prevalence, as many patients are asymptomatic.[3]
Age
The median age of polycythemia vera is 61 years.[3][2] Polycythemia vera occurs in all age groups (including children). The incidence increases with age. Polycythemia vera commonly affects people older than 60 since mutations are more likely to develop with aging.[1][4][5] Younger patients are more likely to develop unusual complications such as mesenteric venous thrombosis. The rate of transformation to acute leukemia is similar as that of older adults.[3]
Gender
Males are more commonly affected with polycythemia vera than females, with a male to female ratio of 6.5:3.5.[1][2][2] However, in patients under age 40, there is a female predominance of 7.5:2.5.
Life expectancy
The life expectancy after diagnosis is 13.5 years.[2] For patients who develop post-PV myelofibrosis or post-PV acute myeloid leukemia, the life expectancy is significantly shorter. Please see Natural History, Complications, and Prognosis section.
References
- ↑ 1.0 1.1 1.2 1.3 National Cancer Institute. Polycythemia vera 2015.http://seer.cancer.gov/seertools/hemelymph/51f6cf57e3e27c3994bd538d/
- ↑ 2.0 2.1 2.2 2.3 2.4 Verstovsek S, Komrokji RS (2015). "Novel and emerging therapies for the treatment of polycythemia vera". Expert Rev Hematol. 8 (1): 101–13. doi:10.1586/17474086.2015.972359. PMC 4934659. PMID 25353086.
- ↑ 3.0 3.1 3.2 3.3 Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK; et al. (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F". J Clin Oncol. 33 (33): 3953–60. doi:10.1200/JCO.2015.61.6474. PMC 4979103. PMID 26324368.
- ↑ Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M (2003). "Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia". Haematologica. 88 (1): 13–8. PMID 12551821.
- ↑ Berlin, NI. (1975). "Diagnosis and classification of polycythemias". Semin Hematol 12: 339.